TCR 4 expressing T cell therapy(MediGene AG)

N/A

Report date: 2024/10/28 11:05:17

Base Information

Drug NameTCR 4 expressing T cell therapy(MediGene AG)
Drug Alias NameTCR-4MDG-10-XXMDG10XX
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMedigene AgInstitute For Research In Immunology And CancerUniversity Of Montreal
China Registration ClassN/A

Develop Information

Active CompaniesInstitute For Research In Immunology And CancerUniversity Of MontrealMedigene Ag +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A